The Patent Finder

ReMYND N.V.

Also on record
Records under this name other than the patents ReMYND N.V. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 6 patents it holds.

Showing 1 to 10 of 10 · Back to ReMYND N.V.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 11,939,324Compounds for the treatment of epilepsy, neurodegenerative disorders and other CNS disorders
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 11,548,881Compounds for the Treatment of Epilepsy, Neurodegenerative Disorders and Other CNS Disorders
Formerly held
In force
 · Medium confidence
In forceMedium confidence
US 8,722,681N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases
Lapsed on the fee record
Ended May 13, 2026 · USPTO record
Lapsed on the fee recordEnded May 13, 2026USPTO record
US 8,618,138Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases
Lapsed on the fee record
Ended Dec 31, 2025 · USPTO record
Lapsed on the fee recordEnded Dec 31, 2025USPTO record
US 9,808,456Piperazine thiazole derivatives useful in the treatment of tauopathies such as Alzheimer's disease
Lapsed on the fee record
Ended Nov 7, 2025 · USPTO record
Lapsed on the fee recordEnded Nov 7, 2025USPTO record
US 8,541,406Thiadiazole derivatives for the treatment of neurodegenerative diseases
Lapsed on the fee record
Ended Sep 24, 2025 · USPTO record
Lapsed on the fee recordEnded Sep 24, 2025USPTO record
US 9,750,7452,7-diazaspiro[3.5]nonane compounds
Lapsed on the fee record
Ended Sep 5, 2025 · USPTO record
Lapsed on the fee recordEnded Sep 5, 2025USPTO record
US 9,617,2642,7-diazaspiro[3.5]nonane compounds
Lapsed on the fee record
Ended Apr 11, 2025 · USPTO record
Lapsed on the fee recordEnded Apr 11, 2025USPTO record
US 10,562,869Oxadiazole compounds
Lapsed on the fee record
Ended Feb 18, 2024 · USPTO record
Lapsed on the fee recordEnded Feb 18, 2024USPTO record
US 7,960,556Thiadiazole derivatives for the treatment of neuro-degenerative diseases
Lapsed on the fee record
Ended Jun 14, 2019 · USPTO record
Lapsed on the fee recordEnded Jun 14, 2019USPTO record
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 20, 2026 · includes USPTO assignment data published Nov 19, 2026, status data published Nov 20, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited